Please assess the completion status of the following clinical trial:

Trial Title: Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of cirrhosis (clinical or by liver biopsy)~* Admission due to acute bleeding from oesophageal or gastric (GOV1 or GOV2) varices~* Child-Pugh Class C (Child-Pugh score less than or equal to 13) or Child-Pugh class B~* Signed written informed consent~Exclusion Criteria:~* Patients not fulfilling inclusion criteria~* Pregnancy or breast-feeding~* Confirmed hepatocellular carcinoma~* Creatinine greater than 3 mg/dl~* Terminal hepatic failure (Child-Pugh score greater than 13)~* Previous treatment with TIPS or combined pharmacological and endoscopic treatment to prevent rebleeding~* Fundal or ectopic gastric variceal bleeding (IGV1 or IGV2)~* Complete portal vein thrombosis or portal cavernoma~* Congestive heart failure New York Heart Association (NYHA) greater than III or medical history of pulmonary hypertension~* Spontaneous recurrent hepatic encephalopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- TIPS treatment (Type: EXPERIMENTAL): Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.TIPS will be performed as soon as possible once the patients are enrolled in the study, always within the first 72 hours after the diagnostic endoscopy (preferably in the first 24 hours).Vasoactive drugs will be continued until the TIPS is performed and antibiotics will be continued for 5-7 days.
- Medical treatment (Type: ACTIVE_COMPARATOR): Initial control of the bleeding episode will be obtained by vasoactive drugs (octreotide, somatostatin or terlipressin), endoscopic band ligation (sclerotherapy if technically difficult or not feasible) and prophylactic antibiotics.Patients will be treated with non-selective beta-blockers (propranolol)on day 5. In case of contraindications or intolerance to beta-blockers, patients will not receive pharmacological treatment (beta-blockers) and the only treatment to prevent rebleeding will be endoscopic band ligation.

Based on this trial design, predict the completion outcome and termination type (if applicable).